Clinical Observation of Clarithromycin Intensive Therapy for Patients with Chronic Rhinosinusitis / 中国药房

ABSTRACT

OBJECTIVE:To investigate therapeutic efficacy and safety of clarithromycin intensive therapy on patients with chronic rhinosinusitis and its effects on serum inflammatory cytokines.METHODS:A total of 186 patients with chronic rhinosinusitis were randomly divided into control group 1 (62 cases),control group 2 (62 cases) and observation group (62 cases).Control group 1 was given Amoxicillin and clavulanate potassium tablet (7∶ 1) 0.457 g,3 times a day.Control group 2 was given Clarithromycin dispersible tablet 0.25 g orally,once a day.Observation group was given Clarithromycin dispersible tablet 0.5 g orally on the first week,twice a day,0.25 g at the second week,twice a day.Both groups were treated for 2 weeks.Clinical efficacies of 3 groups were observed.Clinical symptom score,TNF-α,IL-6 and hs-CRP before and after treatment as well as the occurrence of ADR were observed.RESULTS:Total response rate was in descending orderobservation group (93.55％) ＞control group 2 (80.65％) ＞control group 1 (65.51％),with statistical significance (P＜0.05).Before treatment,there was no statistical significance in clinical symptom score,the levels of TNF-α,IL-6 and hs-CRP among 3 groups (P＞0.05).After treatment,clinical symptom score,the levels of TNF-αt,IL-6 and hs-CRP were significantly lower than before treatment;those indexes of 3 groups were in ascending orderobservation group＜control group 2＜control group 1,with statistical significance (P＜0.05).The incidence of ADR in observation group and control groups were significantly lower than control group 1,with statistical significance (P＜0.05).There was no statistical significance between observation group and control group 2 (P＞0.05).CONCLUSIONS:Clarithromycin intensive therapy shows significant therapeutic efficacy for chronic rhinosinusitis,improves clinical symptoms of patients and reduces the level of serum inflammatory factor without increasing the occurrence of ADR.